Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.
Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P. Schmitz-Winnenthal FH, et al. Oncoimmunology. 2015 Mar 16;4(4):e1001217. doi: 10.1080/2162402X.2014.1001217. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137397 Free PMC article.
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.
Niethammer AG, Lubenau H, Mikus G, Knebel P, Hohmann N, Leowardi C, Beckhove P, Akhisaroglu M, Ge Y, Springer M, Grenacher L, Buchler MW, Koch M, Weitz J, Haefeli WE, Schmitz-Winnenthal FH. Niethammer AG, et al. Among authors: schmitz winnenthal fh. BMC Cancer. 2012 Aug 20;12:361. doi: 10.1186/1471-2407-12-361. BMC Cancer. 2012. PMID: 22906006 Free PMC article. Clinical Trial.
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.
Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. Schmitz-Winnenthal FH, et al. Oncoimmunology. 2018 Jan 16;7(4):e1303584. doi: 10.1080/2162402X.2017.1303584. eCollection 2018. Oncoimmunology. 2018. PMID: 29632710 Free PMC article.
Potential target antigens for immunotherapy in human pancreatic cancer.
Schmitz-Winnenthal FH, Galindo-Escobedo LV, Rimoldi D, Geng W, Romero P, Koch M, Weitz J, Krempien R, Niethammer AG, Beckhove P, Buchler MW, Z'graggen K. Schmitz-Winnenthal FH, et al. Cancer Lett. 2007 Jul 18;252(2):290-8. doi: 10.1016/j.canlet.2007.01.003. Epub 2007 Feb 22. Cancer Lett. 2007. PMID: 17320278
Portal annular pancreas: a systematic review of a clinical challenge.
Harnoss JM, Harnoss JC, Diener MK, Contin P, Ulrich AB, Büchler MW, Schmitz-Winnenthal FH. Harnoss JM, et al. Among authors: schmitz winnenthal fh. Pancreas. 2014 Oct;43(7):981-6. doi: 10.1097/MPA.0000000000000186. Pancreas. 2014. PMID: 25207658 Free PMC article. Review.
23 results